AGP Executive Report
Last update: 11 hours agoCancer care licensing: IMPACT Therapeutics and Pharmanovia signed an exclusive deal worth up to €423.5m for senaparib across Europe (incl. Liechtenstein), UK, Norway, Iceland, Switzerland, Australia, New Zealand, and parts of MENA, aiming to speed access for ovarian/fallopian tube/primary peritoneal cancer patients. COVID-19 vaccination update: The European Commission authorized Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine for people 6 months+, with coverage across EU plus Iceland, Liechtenstein, and Norway. Public health research: A new European push is targeting a “functional cure” for chronic hepatitis B, where millions in the EU/EEA (including Liechtenstein) are infected but often only learn after serious liver damage. Patient safety & counterfeit risk: Ivoclar rolled out a verification approach for authorized dental product distributors, warning that gray-market/counterfeit items can compromise treatment and patient safety. Reproductive health policy: Liechtenstein’s abortion law debate is back in focus, with reporting highlighting how royal veto power has blocked past liberalization efforts.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
